Vibativ telavancin regulatory update

FDA's Anti-Infective Drugs Advisory Committee will meet on Nov. 29 to discuss an NDA from Theravance for Vibativ telavancin to treat nosocomial pneumonia, including ventilator-associated pneumonia known or suspected to be caused by methicillin-resistant

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE